Preparation and application of novel enhanced antigen-binding polypeptide-induced hepatoma-specific CTL cell

A technology specific to liver cancer cells, applied in the direction of fusion peptides, tumor-specific antigens, hybrid peptides, etc., can solve the problems of multiple side reactions, short antibody half-life, expensive treatment costs, etc., to achieve specific enhancement and enhanced effect , the effect of inhibiting lethality

Active Publication Date: 2017-12-19
BEIJING GENE KEY LIFE TECH CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Currently, more clinical applications are specific antibodies against tumor targets. The half-life of antibodies in the body is short, and repeated administration at intervals is required. The treatment cost is expensive and there are many side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of novel enhanced antigen-binding polypeptide-induced hepatoma-specific CTL cell
  • Preparation and application of novel enhanced antigen-binding polypeptide-induced hepatoma-specific CTL cell
  • Preparation and application of novel enhanced antigen-binding polypeptide-induced hepatoma-specific CTL cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1 Synthesis of Liver Cancer-specific Combined Polypeptide

[0044] HLA molecules generally bind to polypeptides of specific length and affinity, and the amino acid residues at specific positions determine the affinity of polypeptides recognized by TCR. We used the SYFPEITHI and BIMAS databases to predict the binding ability of GPC3, AFP, NY-ESO-1 polypeptides and MHC-I molecules, and then compared and scored and screened. We obtained new sequences of GPC3, AFP and NY-ESO-1 with high affinity for HLA molecules: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. After reviewing a large number of relevant literature and patent reports, the above sequences have not been published in related research.

[0045] The amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and the classic antigen peptide group (sequence has been reported) SEQ ID NO: 5 obtained by screening were entrusted to Beijing Baisheng Gene Technology Co., Ltd. adopts TETRAS TM ...

Embodiment 2

[0046] Example 2 Peripheral Blood Mononuclear Cells (PBMC) Extraction

[0047] (1) Separate 20ml of anticoagulated venous blood from patients with HLA-A*0201 positive liver cancer in the morning. Add 15ml Lymphoprep Separation Solution to a 50ml centrifuge tube.

[0048] (2) Slowly add an equal volume of 0.9% sterile normal saline to the anticoagulated venous blood and gently invert three times to mix well.

[0049] (3) Use a 2ml sterile dropper to slowly add the diluted blood to the surface of the lymphocyte separation medium, and do not shake or turn it upside down after all is transferred.

[0050] (4) Balance the centrifuge tube and centrifuge at room temperature for 30 min at 1700 rpm in a horizontal centrifuge (horizontal rotor), ace / brake: 0 / 0.

[0051] (5) Aspirate excess plasma from the uppermost layer. Gently aspirate the lymphocyte layer with a 2ml sterile pipette, transfer to a new 50ml centrifuge tube, and aspirate the lymphocyte layer in all tubes into the sam...

Embodiment 3

[0056] Example 3 Preparation of Antigen Presenting Cells

[0057] (1) Resuspend PBMC obtained by density gradient centrifugation in AIM V medium, add to cell culture dish, 37°C, 5% CO 2 nourish.

[0058] (2) After 3 hours, take out the culture dish, shake it gently, and suck out the suspended cells.

[0059] (3) AIM V medium containing 500 IU / ml of rhIL-4 and 500 IU / ml of rhGM-CSF was added to the culture dish.

[0060] (4) On the 3rd day and the 5th day after culture, the medium was changed in half, and fresh medium containing 500 IU / ml of rhIL-4 and 500 IU / ml of rhGM-CSFAIM V medium was added.

[0061] (5) On the 6th day of culture, a culture medium was added with a final concentration of 10 ng / ml rhTNF-α, 300 IU / ml rhIL-2, and 10 ng / ml rhIL-33.

[0062] (6) Mature dendritic cells were harvested on day 7.

[0063] (7) Mature dendritic cells were harvested by centrifugation, resuspended in AIM V medium, added with a final concentration of 10 μg / ml amino acid sequence of S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to view more

Abstract

The invention provides preparation and an application of a novel enhanced GPC3-AFP-NY-ESO-1 binding polypeptide-induced hepatoma-specific CTL cell. In the preparation and the application provided by the invention, novel hepatoma cell surface antigen polypeptides screened from GPC3, AFP and NY-ESO-1 are selected for sequential fragment ligation. The newly screened GPC3, AFP, and NY-ESO-1 polypeptides are sequentially ligated into a CTL antigen peptide as shown in SEQ ID NO. 4. In the preparation and the application provided by the invention, a novel method and means for efficient and specific tumor killing for a hepatoma cell are established, and the obtained hepatoma-specific killing CTL cell overcomes the key problems of low efficiency of tumor killing and too long culture time, and can specifically enhance the effect of hepatoma immunological therapy, thereby having an application prospect of tumor treatment.

Description

Technical field: [0001] The invention belongs to the field of immune cell preparation, and in particular relates to a preparation method and application of a novel enhanced GPC3-AFP-NY-ESO-1 combined with polypeptide to induce liver cancer-specific CTL cells. Background technique: [0002] my country is a country with a high incidence of primary hepatocellular carcinoma in the world. There are about 1 million new cases of liver cancer every year in the world, and my country accounts for 55%. Statistics from my country's Cancer Registry Network in 2015 show that among males before the age of 60, liver cancer accounted for the highest proportion of deaths. . In recent years, although there have been some breakthroughs in treatment, such as surgery, interventional therapy, and transplantation, the rapid progression and metastasis of liver cancer are still key problems to be overcome. Tumor immunotherapy has become an important means and method for treating and eliminating tum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N5/0783A61K35/17A61P35/00
CPCA61K35/17A61K39/0011C07K14/4748C07K2319/00C12N5/0638C12N5/0639C12N2501/22C12N2501/2302C12N2501/2304C12N2501/2307C12N2501/2315C12N2501/2321C12N2501/2323C12N2501/2333C12N2501/25C12N2501/515C12N2501/998C12N2502/1114
Inventor 闾军陈辉孙文峰
Owner BEIJING GENE KEY LIFE TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap